0 79

Cited 0 times in

Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)

 Kyung Im Kim  ;  Jae Hyun Kim  ;  Eun Hee Ji  ;  Jun Ho Jang  ;  Jin Seok Kim  ;  Ji-Hyun Kwon  ;  Inho Kim  ;  Seonyang Park  ;  Galina Velikova  ;  Sung-Soo Yoon  ;  Jung Mi Oh 
 QUALITY OF LIFE RESEARCH, Vol.25(4) : 881-890, 2016 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage* ; Dose-Response Relationship, Drug* ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Neoplasms/drug therapy ; Psychometrics ; Quality of Life/psychology* ; Reproducibility of Results ; Republic of Korea ; Sickness Impact Profile ; Surveys and Questionnaires* ; Tertiary Care Centers
Hematopoietic stem cell transplantation ; High-dose chemotherapy ; QLQ-HDC29 ; Quality of life ; Validation
PURPOSE: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. METHODS: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. RESULTS: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach's α, except for the scales body image and the inpatient issues. Cronbach's α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. CONCLUSIONS: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.